Field of the Invention

The present invention relates to compounds of formula I and/or II, which are inhibitors of VDAC1 for treating prediabetes and diabetes, prevent diabetes disease progression (deterioration) and prevent progression of prediabetes to diabetes.

Background Art

Diabetes is a severe metabolic disease that shortens life expectancy through cardiovascular and chronic kidney diseases, as well as causing stroke, peripheral nerve disease and blindness. Approximately 12% of global health costs are spent on diabetes. Diabetes is due to either the pancreas not producing enough insulin or the cells of the body not responding properly to the insulin produced. There are two main types of diabetes: Type 1 Diabetes Mellitus (T1D) and type 2 diabetes mellitus (T2D). T1D is one of the most common multifactorial endocrine and metabolic diseases in childhood resulting in persistent hyperglycemia, due to autoimmune destruction of the insulin-producing beta cells in the pancreatic islets. T1D requires life-long insulin therapy. Several studies have reported that residual beta-cells (b cells) remain in the pancreatic islets of T1D patients. In fact, up to 40-50% of beta-cells may escape destruction, but insulin secretion is insufficient to maintain normal blood glucose regulation. In vitro culture of islets from T1D subjects at physiological glucose concentration has shown time-dependent improvement of glucose-stimulated insulin secretion (Lupi R, et al. 2004. Diabetes/metabolism research and reviews, 5 20(3), 246-251; Krogvold L et al. 2015. Diabetes 64:2506-2512; Brissova M. et al. 2018 Cell Rep. 22:2667-2676). These results suggest that the residual beta-cells are dysfunctional in vivo but can resume regulated insulin secretion after extraction from the harmful in vivo environment. Type 2 diabetes (T2D) is a world-wide health problem in the wake of the obesity epidemic. Approximately 400 million people world-wide suffer from T2D and 320 million are estimated to have pre-diabetes (Zimmet P and Alberti KG. 2016. Nature Rev Endo 10:616-622). Normoglycemia is maintained when obesity-associated insulin resistance is compensated by increased insulin secretion. T2D has a strong genetic component and most frequently occurs when members of diabetes-prone families cumulate risk factors, such as obesity, smoking, repeated pregnancies or shift work. It appears that the disease occurs as a sequel of obesity, when the insulin secretion from the pancreatic beta cells cannot adapt to the increased insulin requirements of the organs resistant to the hormone.

T2D develops after years of increased fasting blood glucos (FBG) and/or impaired glucose tolerance (IGT), criteria defining prediabetes (Ligthart S, et al. 2016. Lancet Diabetes & 20 endocrinology 4:44-51). Elevated average blood glucose concentrations exert harmful effects on most cells in the body, including endothelial cells and beta cells, so called glucotoxicity (Hansen NW, et al. IUBMB Life, 69:148- 161, 2017 ; Weir GC et al. 2004. Diabetes 53, Suppl 3: S16-21). Glucotoxicity contributes to b cell decompensation, a phenomenon which also exists in healthy subjects as glucose infusion attenuates glucose-stimulated insulin secretion (GSIS). The overt T2D with hyperglycemia, increased urine volume and thirst is preceded by a period of prediabetes, often lasting up to 7 years. Prediabetes is defined as elevated fasting blood glucose or impaired lowering of blood glucose after an oral glucose challenge. T2D is reversible early after onset of the disease by life-style interventions aiming at weight loss and implementing physical exercise (Al-Mrabeh et al., 2016. Diabetologia 59:1753-1759). Such interventions show, however, low patient compliance.

In healthy cells, Voltage-dependent anion channel (VDAC), a multi-functional protein, is positioned at the crossroad of metabolic and survival pathways considered a master-gatekeeper regulating the flux of metabolites and ions between mitochondria and the cytosol. Of the three VDAC isoforms, VDACl and VDAC2 mediate ADP/ATP exchange and calcium flux in mitochondria, while VDAC3 function is less clear (Shoshan-Barmatz V et al., 2015; Biochim. Biophys. Acta 1848:2547-2575; Shoshan-Barmatz V et al., 2010. Molecular aspects of medicine 31:227-285). VDAC has also been localized to cell compartments other than mitochondria, such as the plasma membrane of various cells, the sarcoplasmic reticulum of skeletal muscles, the endoplasmic reticulum (ER) of rat cerebellum, and in synaptosomes from the Torpedo electric organ (De Pinto V et al., FEBS Lett. 2010. 584:1793-1799). In endothelial cells, VDACl is expressed at the plasma membrane even under physiological conditions (Li L et al. J Biol Chem 2014, 289:32628-38. ). The mechanism underlying plasma membrane localization of VDACl in certain cell types remains to be elucidated. VDACl also plays a key role in apoptosis, participating in the release of apoptotic factors from mitochondria and interacting with anti-apoptotic regulators (Shoshan-Barmatz et al., 2015, ibid; Shoshan-Barmatz et al., 2010, ibid). 10186PC00 Mitochondrial proteome analysis reveals altered expression of VDAC and multiple other proteins involved in nutrient metabolism, ATP synthesis, cellular defense, glycoprotein folding and mitochondrial DNA stability in rat clonal pancreatic β-cells exposed to high glucose (Ahmed, M. et al., Islets 2010, 2:283-292). Under glucotoxic condition, the expression of VDAC1 was upregulated while that of VDAC2 was downregulated. In islets of human T2D organ donors, VDAC1 mRNA and protein are upregulated, while VDAC2 levels are downregulated (Zhang E. et al.2019 Cell Metabolism 29: 64-77). VDAC1 was mistargeted to the plasma membrane in the beta cells of T2D organ donours and such translocation was reproduced when islets from non-diabetic organ donors were cultured under glucotoxic conditions. Remarkably, the plasma membrane expression of VDAC1 resulted in loss of ATP, a coupling factor essential for glucose-stimulated insulin secretion (GSIS). Prevention of the loss of ATP by acute exposure of the T2D islets to an antibody against VDAC1 or a chemical VDAC1 inhibitor, N-(4-chlorophenyl)-4-hydroxy-3-{4-[4- (trifluoromethoxy)phenyl]piperazin-1-yl}butanamide (CAS number: 2086257-77-2), restored GSIS. Inhibition of VDAC1 function in vitro does not affect insulin secretion, nor is glycemia altered in non-diabetic control mice (Zhang et al. Cell Metabolism ibid). Summary of the invention In a first aspect the present invention relates to a compound of general formula wherein R ¹ -R ⁵ are independently selected from the group consisting of hydrogen, halogen, CN, NO ₂ , CF ₃ , quaternary ammonium, COOH, COO-C _1-6 alkyl, OCF ₃ , SCF ₃ , SO ₃ -C _1-6 alkyl, provided that at least one of R ¹ -R ⁵ is not hydrogen, R ⁶ is selected from C _1-3 -R ⁸ , wherein R ⁸ is selected from H, OH, SH, and NH ₂ , 3 R ⁷ is selected from the group consisting of a) aryl substituted with one or more groups selected from hydrogen, halogen, CN, C _1-3 alkyl, NO ₂ , CONH ₂ , NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl, provided that at least one of said groups is not hydrogen; b) pyridyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; c) pyrrolidinyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; d) pyrazolyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; e) thiazolyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; f) C _5-7 cycloalkyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; g) NHCONH ₂ ; h) C _1-3 alkyl optionally substituted with a group selected from CONH ₂ , CON(CH ₃ ) ₂ , CF ₃ , and C _2-4 alken; X is -CONH- or -NHCO-, or X-R ⁷ taken together is CONR’R’’, wherein R’ and R’’ together with the nitrogen forms a monoheterocyclic ring or a biheterocyclic group selected from a) a monoheterocyclic ring having 4-7 ring atoms wherein 1-2 is selected from nitrogens and 0-2 from oxygens and the remaining ring atoms are carbon, and optionally substituted with a group selected from oxo, OH, C _1-3 alkyl-CN, or b) a biheterocyclic group having 7-10 ring atoms wherein 1-4 is selected from nitrogens and the remaining ring atoms are carbon, and optionally substituted with a group selected from oxo, OH, C _1-3 alkyl-CN; Hy is a non-aromatic heterocyclic system selected from a) a monoheterocyclic ring having 4-7 ring atoms, wherein 2-3 ring atoms are N, 0-1 ring atoms is O and 0-1 ring atoms is S, and the remaining ring atoms are carbon, provided that if the monoheterocyclic ring is piperazine, then R ⁶ is not CH ₂ OH or X is not -CONH-, wherein the attachment point of the monoheterocyclic ring to the phenyl ring having substituents R ¹ -R ⁵ of formula I is different from the attachment point of the monoheterocyclic ring to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I, b) a biheterocyclic group having a first and a second heterocyclic ring which are fused, the biheterocyclic group having from 6 to 12 ring atoms wherein 2-4 ring atoms are N, 0-2 ring atoms is O, 0-2 ring atoms is S, and the remaining ring atoms are carbon, wherein the first heterocyclic ring is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula I, and the second heterocyclic ring is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I, c) a spiroheterocyclic group having a first and a second heterocyclic ring which are connected and share one carbon atom, the spiroheterocyclic group having from 6 to 12 ring atoms wherein 2-4 ring atoms are N, 0-2 ring atoms is O, 0-2 ring atoms is S, and the remaining ring atoms are carbon, wherein the first heterocyclic ring is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula I, and the second heterocyclic ring is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I, or d) a first and a second monoheterocyclic ring connected by a linker, such as a bond, e.g. a sp ² or sp ³ hybridized bond, wherein each monoheterocyclic ring is independently selected from a monoheterocyclic ring having 4-7 ring atoms, wherein 1-3 ring atoms are N, 0-1 ring atoms is O and 0-1 ring atoms is S, and the remaining ring atoms are carbon, wherein the first monoheterocyclic ring is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula I, and the second monoheterocyclic ring is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I; or a pharmaceutically acceptable salt or solvate thereof. In an embodiment R ¹ is selected from halogen, CN, NO ₂ , CF ₃ , quaternary ammonium, COOH, COO-C _1-6 alkyl, OCF ₃ , SCF ₃ , SO ₃ -C _1-6 alkyl; and R ² -R ⁵ are hydrogen. In anonther embodiment R ² is selected from halogen, CN, NO ₂ , CF ₃ , quaternary ammonium, COOH, COO-C _1-6 alkyl, OCF ₃ , SCF ₃ , SO ₃ -C _1-6 alkyl; and R ¹ , R ³ -R ⁵ are hydrogen. In a further embodiment R ³ is selected from halogen, CN, NO ₂ , CF ₃ , quaternary ammonium, COOH, COO-C _1-6 alkyl, OCF ₃ , SCF ₃ , SO ₃ -C _1-6 alkyl; and R ¹ , R ² , R ⁴ -R ⁵ are hydrogen; typically R ³ is OCF ₃ . In a still further embodiment R ⁴ is selected from halogen, CN, NO ₂ , CF ₃ , quaternary ammonium, COOH, COO-C _1-6 alkyl, OCF ₃ , SCF ₃ , SO ₃ -C _1-6 alkyl; and R ¹ - R ³ , R ⁵ are hydrogen. In a further embodiment R ⁵ is selected from halogen, CN, NO ₂ , CF ₃ , quaternary ammonium, COOH, COO-C _1-6 alkyl, OCF ₃ , SCF ₃ , SO ₃ -C _1-6 alkyl; and R ¹ - R ⁴ are hydrogen. In a still further embodiment R ⁶ is selected from C _1-3 -R ⁸ , wherein R ⁸ is OH, typically CH ₂ OH. In a further embodiment R ⁷ is selected from the group consisting of a) a phenyl substituted with one or more groups selected from hydrogen, halogen, CN, C _{1- 3} alkyl, NO ₂ , CONH ₂ , NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl, provided that at least one of said groups is not hydrogen; typically, phenyl substituted with a group selected from halogen, CF ₃ , OCH ₃ , NHCOCH ₃ , CN, CH ₃ , and SO ₂ CH ₃ , b) a pyridyl optionally substituted with one or more halogen; c) a pyrrolidinyl substituted with one or more NHCO-C _1-3 alkyl; d) a pyrazolyl optionally substituted with one or more CONH ₂ ; e) a thiazolyl; f) a cyclohexyl substituted with one or more CN alkyl; g) a NHCONH ₂ ; and h) a C _1-2 alkyl substituted with a group selected from CON(CH ₃ ) ₂ , CF ₃ , and C ₂ alken. In an alternative embodiment X-R ⁷ taken together is CONR’R’’, wherein R’ and R’’ together with the nitrogen forms a monoheterocyclic ring or a biheterocyclic group selected from a) a monoheterocyclic group having 5 ring atoms wherein 1-2 is selected from nitrogens and the remaining ring atoms are carbon, and optionally substituted with a group selected from oxo, OH, CH ₂ -CN, or b) a biheterocyclic group having 9-10 ring atoms wherein 1-3 is selected from nitrogens and the remaining ring atoms are carbon. In a further embodiment X is -CONH-. In another embodiment X is -NHCO-. In a still further embodiment Hy is a non-aromatic cyclic system selected from a) wherein the monoheterocyclic ring has 6-7 ring atoms, wherein 2 are N, and the remaining ring atoms are carbon, such as piperazin or homopiperazin. In a further embodiment Hy is a non-aromatic cyclic system selected from b) wherein the biheterocyclic group has from 8 to 11 ring atoms wherein 1-2 is N, 0-1 is O and the remaining ring atoms are carbon. In a still further embodiment Hy is a non-aromatic cyclic system selected from c) wherein the spiroheterocyclic group has from 8 to 11 ring atoms wherein 2-3 ring atoms are N, 0-1 ring atoms is O, and the remaining ring atoms are carbon. In a further embodiment Hy is a non-aromatic cyclic system selected from d) wherein the first and second monoheterocyclic ring is connected by a bond, and the first monoheterocyclic ring has from 4-6 ring atoms, wherein 1-2 is N and 0-1 is O, and the remaining ring atoms are carbon, and the second monoheterocyclic ring has from 4-6 ring atoms, wherein 1-2 is N and 0-1 is O, and the remaining ring atoms are carbon. In a still further embodiment, the compound of general formula I is a compound of formula II wherein R ¹ -R ⁵ are independently selected from the group consisting of hydrogen, halogen, CN, NO2, CF3, quaternary ammonium, COOH, COO-C1-6 alkyl, OCF3, SCF ₃ , SO ₃ -C _1-6 alkyl, provided that at least one of R ¹ -R ⁵ is not hydrogen, R ⁶ is selected from C _1-3 -R ⁸ , wherein R ⁸ is selected from H, OH, SH, and NH ₂ , R ⁷ is selected from the group consisting of a) aryl substituted with one or more groups selected from hydrogen, halogen, CN, C _1-3 alkyl, NO ₂ , CONH ₂ , NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl, provided that at least one of said groups is not hydrogen; b) pyridyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; c) pyrrolidinyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; d) pyrazolyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; e) thiazolyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; f) C _5-7 cycloalkyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; g) NHCONH ₂ ; h) C _1-3 alkyl optionally substituted with a group selected from CONH ₂ , CON(CH ₃ ) ₂ , CF ₃ , and C _2-4 alken; X is -CONH- or -NHCO-, or X-R ⁷ taken together is CONR’R’’, wherein R’ and R’’ together with the nitrogen forms a monoheterocyclic ring or a biheterocyclic group selected from a) a monoheterocyclic ring having 4-7 ring atoms wherein 1-2 is selected from nitrogens and 0-2 fromoxygens and the remaining ring atoms are carbon, and optionally substituted with a group selected from oxo, OH, C _1-3 alkyl-CN, or b) a biheterocyclic group having 7-10 ring atoms wherein 1-4 is selected from nitrogens and the remaining ring atoms are carbon, and optionally substituted with a group selected from oxo, OH, C _1-3 alkyl-CN; is a non-aromatic heterocyclic system having a first and a second nitrogen as attachment point selected from a) a monoheterocyclic ring having 4-7 ring atoms, wherein 2-3 ring atoms are N, 0-1 ring atoms is O and 0-1 ring atoms is S, and the remaining ring atoms are carbon, provided that if the monoheterocyclic ring is piperazine, then R ⁶ is not CH ₂ OH or X is not -CONH-, wherein the first nitrogen of the monoheterocyclic ring is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula I and the second nitrogen of the monoheterocyclic ring is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I, b) a biheterocyclic group having a first and a second heterocyclic ring which are fused, the biheterocyclic group having from 6 to 12 ring atoms wherein 2-4 ring atoms are N, 0-2 ring atoms is O, 0-2 ring atoms is S, and the remaining ring atoms are carbon, wherein the first nitrogen of the first heterocyclic ring is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula I and the second nitrogen of the second heterocyclic ring is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I, c) a spiroheterocyclic group having a first and a second heterocyclic ring which are connected and share one carbon atom, the spiroheterocyclic group having from 6 to 12 ring atoms wherein 2-4 ring atoms are N, 0-2 ring atoms is O, 0-2 ring atoms is S, and the remaining ring atoms are carbon, wherein the first nitrogen of the first heterocyclic ring is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula I and the second nitrogen of the second heterocyclic ring is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I, or d) a first and a second monoheterocyclic ring connected by a linker, such as a bond, wherein each monoheterocyclic ring is independently selected from a monoheterocyclic ring having 4-7 ring atoms, wherein 1-3 ring atoms are N, 0-1 ring atoms is O and 0-1 ring atoms is S, and the remaining ring atoms are carbon, wherein the first nitrogen of the first monoheterocyclic ring is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula I, and the second nitrogen of the second monoheterocyclic ring is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula I; or a pharmaceutically acceptable salt or solvate thereof. In a further embodiment the compound of formula I is selected from any one of 4-Chloro-N-(3-hydroxy-2-{4-[4-(trifluoromethoxy)phenyl]piper azin-1- yl}propyl)benzamide, N-(4-Chlorophenyl)-5-hydroxy-3-{4-[4-(trifluoromethoxy)pheny l]piperazin-1- yl}pentanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{4-[4-(trifluoromethoxy)pheny l]-1,4-diazepan-1- yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-(3-{1-[4-(trifluoromethoxy)ph enyl]azetidin-3- yl}piperidin-1-yl)butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{6-[4-(trifluoromethoxy)pheny l]-2,6- diazaspiro[3.4]octan-2-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{1-[4-(trifluoromethoxy)pheny l]-octahydro-1H- pyrrolo[3,2-b]pyridin-4-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- octahydropyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{8-[4-(trifluoromethoxy)pheny l]-2,8- diazaspiro[5.5]undecan-2-yl}butanamide, N-[(Dimethylcarbamoyl)methyl]-4-hydroxy-3-{2-[4-(trifluorome thoxy)phenyl]-6- oxa-2,9-diazaspiro[4.5]decan-9-yl}butanamide, 3-(4-Hydroxy-3-{2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-dia zaspiro[4.5]decan-9- yl}butanamido)pyrrolidine-1-carboxamide, N-[2-(Dimethylcarbamoyl)ethyl]-4-hydroxy-3-{2-[4-(trifluorom ethoxy)phenyl]-6- oxa-2,9-diazaspiro[4.5]decan-9-yl}butanamide, 5-(4-Hydroxy-3-{2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-dia zaspiro[4.5]decan-9- yl}butanamido)-1H-pyrazole-3-carboxamide, 4-Hydroxy-N-(2,2,2-trifluoroethyl)-3-{2-[4-(trifluoromethoxy )phenyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-3-{2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-diazas piro[4.5]decan-9-yl}- N-[4-(trifluoromethyl)phenyl]butanamide, N-(5-Chloropyridin-2-yl)-4-hydroxy-3-{2-[4-(trifluoromethoxy )phenyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-N-(3-methoxyphenyl)-3-{2-[4-(trifluoromethoxy)phen yl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Acetamidophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)ph enyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(3-Acetamidophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)ph enyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Cyanophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)phenyl ]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(2-Chlorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(3-Chlorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Fluorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 1-(4-Hydroxy-3-{2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-dia zaspiro[4.5]decan-9- yl}butanoyl)imidazolidin-4-one, 4-Hydroxy-N-(prop-2-en-1-yl)-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-1-(pyrazolidin-1-yl)-3-{2-[4-(trifluoromethoxy)phe nyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butan-1-one, 4-Hydroxy-1-(3-hydroxypyrrolidin-1-yl)-3-{2-[4-(trifluoromet hoxy)phenyl]-6-oxa- 2,9-diazaspiro[4.5]decan-9-yl}butan-1-one, 2-[1-(4-Hydroxy-3-{5-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4 H,5H,6H- pyrrolo[3,4-c]pyrrol-2-yl}butanoyl)pyrrolidin-3-yl]acetonitr ile, N-(3-chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-N-(pyridin-3-yl)-3-{5-[4-(trifluoromethoxy)phenyl] - 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-N-(1,2-thiazol-5-yl)-3-{5-[4-(trifluoromethoxy)phe nyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-[(Dimethylcarbamoyl)methyl]-4-hydroxy-3-{5-[4-(trifluorome thoxy)phenyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-(2-Chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-N-(1H-pyrazol-1-yl)-3-{2-[4-(trifluoromethoxy)phen yl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Cyanophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)phenyl ]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-1-{1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl}-3-{ 5-[4- (trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]py rrol-2-yl}butan-1- one, 4-Hydroxy-N-[(1r,4r)-4-cyanocyclohexyl]-3-{2-[4-(trifluorome thoxy)phenyl]-6-oxa- 2,9-diazaspiro[4.5]decan-9-yl}butanamide, N-(Carbamoylamino)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-N-(pyridin-2-yl)-3-{2-[4-(trifluoromethoxy)phenyl] -6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-N-(pyridin-3-yl)-3-{2-[4-(trifluoromethoxy)phenyl] -6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-3-{5-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6 H-pyrrolo[3,4- c]pyrrol-2-yl}-N-(2,4,6-trimethylphenyl)butanamide, 4-Hydroxy-N-(4-methanesulfonylphenyl)-3-{2-[4-(trifluorometh oxy)phenyl]-6-oxa- 2,9-diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-1-{1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-5-yl}-3-{5 -[4- (trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]py rrol-2-yl}butan-1- one; or a pharmaceutically acceptable salt or solvate thereof. Each of the above listed compounds or a pharmaceutically acceptable salt or solvate thereof are individual embodiments and may be subject to one or more independent claims. In a still further embodiment the compound of formula I is selected from any one of 4-Chloro-N-(3-hydroxy-2-{4-[4-(trifluoromethoxy)phenyl]piper azin-1- yl}propyl)benzamide, N-(4-Chlorophenyl)-5-hydroxy-3-{4-[4-(trifluoromethoxy)pheny l]piperazin-1- yl}pentanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{4-[4-(trifluoromethoxy)pheny l]-1,4-diazepan-1- yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-(3-{1-[4-(trifluoromethoxy)ph enyl]azetidin-3- yl}piperidin-1-yl)butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{6-[4-(trifluoromethoxy)pheny l]-2,6- diazaspiro[3.4]octan-2-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{1-[4-(trifluoromethoxy)pheny l]-octahydro-1H- pyrrolo[3,2-b]pyridin-4-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- octahydropyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-(4-Chlorophenyl)-4-hydroxy-3-{8-[4-(trifluoromethoxy)pheny l]-2,8- diazaspiro[5.5]undecan-2-yl}butanamide, N-[(Dimethylcarbamoyl)methyl]-4-hydroxy-3-{2-[4-(trifluorome thoxy)phenyl]-6- oxa-2,9-diazaspiro[4.5]decan-9-yl}butanamide, N-[2-(Dimethylcarbamoyl)ethyl]-4-hydroxy-3-{2-[4-(trifluorom ethoxy)phenyl]-6- oxa-2,9-diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-N-(2,2,2-trifluoroethyl)-3-{2-[4-(trifluoromethoxy )phenyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-3-{2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-diazas piro[4.5]decan-9-yl}- N-[4-(trifluoromethyl)phenyl]butanamide, N-(5-Chloropyridin-2-yl)-4-hydroxy-3-{2-[4-(trifluoromethoxy )phenyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-N-(3-methoxyphenyl)-3-{2-[4-(trifluoromethoxy)phen yl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Acetamidophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)ph enyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(3-Acetamidophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)ph enyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Cyanophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)phenyl ]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(2-Chlorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(3-Chlorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Fluorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 1-(4-Hydroxy-3-{2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-dia zaspiro[4.5]decan-9- yl}butanoyl)imidazolidin-4-one, 4-Hydroxy-N-(prop-2-en-1-yl)-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-1-(pyrazolidin-1-yl)-3-{2-[4-(trifluoromethoxy)phe nyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butan-1-one, 4-Hydroxy-1-(3-hydroxypyrrolidin-1-yl)-3-{2-[4-(trifluoromet hoxy)phenyl]-6-oxa- 2,9-diazaspiro[4.5]decan-9-yl}butan-1-one, 2-[1-(4-Hydroxy-3-{5-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4 H,5H,6H- pyrrolo[3,4-c]pyrrol-2-yl}butanoyl)pyrrolidin-3-yl]acetonitr ile, N-(3-chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-N-(pyridin-3-yl)-3-{5-[4-(trifluoromethoxy)phenyl] - 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-N-(1,2-thiazol-5-yl)-3-{5-[4-(trifluoromethoxy)phe nyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-[(Dimethylcarbamoyl)methyl]-4-hydroxy-3-{5-[4-(trifluorome thoxy)phenyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, N-(2-Chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-N-(1H-pyrazol-1-yl)-3-{2-[4-(trifluoromethoxy)phen yl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, N-(4-Cyanophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)phenyl ]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl}butanamide, 4-Hydroxy-1-{1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl}-3-{ 5-[4- (trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]py rrol-2-yl}butan-1- one, 4-Hydroxy-N-[(1r,4r)-4-cyanocyclohexyl]-3-{2-[4-(trifluorome thoxy)phenyl]-6-oxa- 2,9-diazaspiro[4.5]decan-9-yl}butanamide, N-(Carbamoylamino)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-N-(pyridin-2-yl)-3-{2-[4-(trifluoromethoxy)phenyl] -6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-N-(pyridin-3-yl)-3-{2-[4-(trifluoromethoxy)phenyl] -6-oxa-2,9- diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-3-{5-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6 H-pyrrolo[3,4- c]pyrrol-2-yl}-N-(2,4,6-trimethylphenyl)butanamide, 4-Hydroxy-N-(4-methanesulfonylphenyl)-3-{2-[4-(trifluorometh oxy)phenyl]-6-oxa- 2,9-diazaspiro[4.5]decan-9-yl}butanamide, 4-Hydroxy-1-{1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-5-yl}-3-{5 -[4- (trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]py rrol-2-yl}butan-1- one; or a pharmaceutically acceptable salt or solvate thereof. The compounds presented herein are intended to include all diastereomeric, enantiomeric, atropisomers, and epimeric forms as well as the appropriate mixtures thereof. In a second aspect the present invention relates to a compound of any one of the above aspect or embodiments for use as a medicament and for use in a method for treating diabetes or pre-diabetes, in a subject in need thereof, i.e., for use in treatment of diabetes or pre-diabetes. Typically, the diabetes is type 2. A related as aspect of the invention defines use of a compound of any one of the above aspect or embodiments in the manufacture of a medicmant for treating diabetes or pre-diabetes. In a third aspect the present invention relates to a method for treating diabetes or pre-diabetes in a subject in need thereof. The method coprises administering to the subject a therapeutically effective amount of a compound of formula I or II. In a fourth aspect the present invention relates to a method for preventing the progress of diabetes and/or preventing progress of prediabetes to diabetes and/or reversal of diabetes and/or for reversal of diabetes due to reversal of beta cell dysfunction in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of a compound of formula I or II. To be sufficiently capable of treating diabetes or pre-diabetes in a human subject the compound of formula I or II should have a high affinity to VDAC1 and inhibit VDAC1 function. In this respect, the specific binding to VDAC1 is a K _D value of less than 15 µM (wherein µM means micromolar), such as less than 10 µM such as less than 5 µM, and in a preferred embodiment less than 1 µM, as measured in a Microscale Thermophoresis (MST) binding assay, typically in the MST assay as described herein. Further objects and advantages of the present invention will appear from the following description, and claims. Brief description of figures Figure 1 shows an MST plot of the compound of example 4. Description of the invention The present invention relates to a compound of formula I binding to the Voltage-Dependent Anion Channel Type 1 (VDAC1) protein and its use in the treatment of diabetes or pre-diabetes. Compounds binding VDAC1 can reduce the VDAC1 channel conductance and inhibits VDAC1-mediated metabolite transport, particularly inhibiting VDAC1 translocated to the plasma membrane of pancreatic β-cells. In a first aspect the present invention relates to a compound of general formula I wherein R ¹ -R ⁷ , Hy and X are as defined in claim 1. In a preferred embodiment R ³ is selected from halogen, CN, NO ₂ , CF ₃ , quaternary ammonium, COOH, COO-C _1-6 alkyl, OCF ₃ , SCF ₃ , SO ₃ -C _1-6 alkyl; and R ¹ , R ² , R ⁴ -R ⁵ are hydrogen. In a further preferred embodiment R ¹ , R ² , R ⁴ -R ⁵ are hydrogen and R ³ is OCF ₃ . In a further embodiment R ⁶ is selected from C _1-3 -R ⁸ , wherein R ⁸ is OH. In a preferred embodiment R ⁶ is selected from C _1-2 -R ⁸ , wherein R ⁸ is OH. Typically, R ⁶ is CH ₂ CH ₂ OH or CH ₂ OH. In a further embodiment R ⁷ is a phenyl substituted with one, two or three groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH ₂ , NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl, and the remaining substituents are hydrogen. Typically, R ⁷ is phenyl substituted with one or two groups, such as one group, selected from halogen, CF ₃ , OCH ₃ , NHCOCH ₃ , CN, CH ₃ , and SO ₂ CH ₃ . In a still further embodiment R ⁷ is a pyridyl. In another embodiment R ⁷ is a pyridyl substituted with one or more halogen, such as phenyl substituted with one halogen, e.g. one Cl. In a further embodiment R ⁷ is a pyrrolidinyl substituted with one or more CONH ₂ . In a typical embodiment R ⁷ is a pyrrolidinyl substituted with one CONH ₂ . In a further embodiment R ⁷ is a pyrazolyl. In a further embodiment R ⁷ is a pyrazolyl substituted with one or two CONH ₂ , such as one CONH ₂ . In a further embodiment R ⁷ is a thiazolyl. In a further embodiment R ⁷ is a cyclohexyl substituted with one or two CN, such as one CN. In a further embodiment R ⁷ is a NHCONH ₂ . In a further embodiment R ⁷ is a C _1-2 alkyl substituted with one group selected from CON(CH ₃ ) ₂ , CF ₃ , and C ₂ alken. In a further embodiment R ⁷ is a CH ₂ substituted with one group selected from CON(CH ₃ ) ₂ , CF ₃ , and C ₂ alken. In another embodiment R ⁷ is a CH ₂ CH ₂ substituted with one group selected from CON(CH ₃ ) ₂ . In one alternative embodiment X-R ⁷ taken together is CONR’R’’, wherein R’ and R’’ together with the nitrogen forms a monoheterocyclic group having 5 ring atoms wherein 1-2 is selected from nitrogens and the remaining ring atoms are carbon, and optionally substituted with a group selected from oxo, OH, CH ₂ -CN. In a further embodiment R’ and R’’ together with the nitrogen forms a monoheterocyclic group having 5 ring atoms wherein 1-2 is selected from nitrogens and the remaining ring atoms are carbon, such as imidazolidinyl, pyrazolidinyl, pyrrolidinyl. In a still further embodiment R’ and R’’ together with the nitrogen forms a monoheterocyclic group having 5 ring atoms wherein 1-2 is selected from nitrogens and the remaining ring atoms are carbon, substituted with one or two groups, such as one group, selected from oxo, OH, CH ₂ -CN, typically imidazolidinyl substituted with one or two groups, such as one group, selected from oxo, or pyrrolidinyl substituted with one or two groups, such as one group, selected from OH and CH ₂ -CN, In another alternative embodiment X-R ⁷ taken together is CONR’R’’, wherein R’ and R’’ together with the nitrogen forms a biheterocyclic group having 9 ring atoms wherein 1-3 is selected from nitrogens and the remaining ring atoms are carbon. In a still further embodiment R’ and R’’ together with the nitrogen forms a biheterocyclic group having 9 ring atoms wherein 3 are selected from nitrogens and the remaining ring atoms are carbon; typically the biheterocyclic group is a 1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridinyl, such as a 1H,4H,5H,6H,7H-pyrazolo[4,3- c]pyridine-5-yl. In a further embodiment X is -CONH-. In another embodiment X is -NHCO-. In a still further embodiment Hy is a non-aromatic cyclic system selected from a) wherein the monoheterocyclic ring has 6 ring atoms, wherein 2 are N, and the remaining ring atoms are carbon, such as piperazin, typically, piperazin-1-yl. In another embodiment Hy is a non-aromatic cyclic system selected from a) wherein the monoheterocyclic ring has 7 ring atoms, wherein 2 are N, and the remaining ring atoms are carbon, such as homopiperazin, typically 1,4-diazepan-1-yl. In a further embodiment Hy is a non-aromatic cyclic system selected from b) wherein the biheterocyclic group has 8 ring atoms wherein 2 is N and the remaining ring atoms are carbon, such as 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol or octahydropyrrolo[3,4-c]pyrrol. In a still further embodiment Hy is a non-aromatic cyclic system selected from b) wherein the biheterocyclic group has 9 ring atoms wherein 2 is N and the remaining ring atoms are carbon, such as octahydro-1H-pyrrolo[3,2-b]pyridinyl. In a further embodiment Hy is a non-aromatic cyclic system selected from c) wherein the spiroheterocyclic group has 8 ring atoms wherein 2 ring atoms are N and the remaining ring atoms are carbon, such as 2,6-diazaspiro[3.4]octanyl. In a still further embodiment Hy is a non-aromatic cyclic system selected from c) wherein the spiroheterocyclic group has 10 ring atoms wherein 2 ring atoms are N and 1 ring atom is O and the remaining ring atoms are carbon, such as 6-oxa-2,9- diazaspiro[4.5]decanyl. In some embodiments Hy is selected from a non-aromatic cyclic system selected from c) and in such situations it is preferred that R ⁷ is selected from the group consisting of a) aryl substituted with one or more groups selected from hydrogen, halogen, CN, C _1-3 alkyl, NO ₂ , CONH ₂ , NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ - C _1-3 alkyl, provided that at least one of said groups is not hydrogen; b) pyridyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; c) pyrrolidinyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; d) pyrazolyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ -C _1-3 alkyl; e) thiazolyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ - C _1-3 alkyl; f) C _5-7 cycloalkyl optionally substituted with one or more groups selected from halogen, CN, C _1-3 alkyl, NO ₂ , CONH _2, NHCO-C _1-3 alkyl, CF ₃ , tertiary ammonium, COOH, COO-C _1-6 alkyl, OC _1-3 alkyl, OCF ₃ , SCF ₃ , SO ₂ -C _1-3 alkyl, SO ₃ - C _1-3 alkyl; g) NHCONH ₂ ; h) C _1-3 alkyl optionally substituted with a group selected from CONH ₂ , CON(CH ₃ ) ₂ , CF ₃ , and C _2-4 alken. In a further embodiment 3-(4-hydroxy-3-{2-[4-(trifluoromethoxy)phenyl]-6- oxa-2,9-diazaspiro[4.5]decan-9-yl}butanamido)- pyrrolidine-1-carboxamide is disclaimed. In a still further embodiment 5-(4-hydroxy-3-{2-[4- (trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]decan-9-y l}butanamido)-1H- pyrazole-3-carboxamide is disclaimed. In a still further embodiment Hy is a non-aromatic cyclic system selected from c) wherein the spiroheterocyclic group has 11 ring atoms wherein 2 ring atoms are N and the remaining ring atoms are carbon, such as 2,8-diazaspiro[5.5]undecanyl. In a further embodiment Hy is a non-aromatic cyclic system selected from d) wherein the first and second monoheterocyclic ring is connected by a bond, and the first monoheterocyclic ring has 4 ring atoms, wherein 1 is N and the remaining ring atoms are carbon, and the second monoheterocyclic ring has 6 ring atoms, wherein 1 is N and the remaining ring atoms are carbon, such as azetidin-3-yl-piperidinyl. In a still further embodiment the compound of general formula I is a compound of formula II wherein R ¹ -R ⁷ and X are are as defined in claim 1. All embodiments described above in connection with ifrst aspect relating to the compound of formula I are also embodiments of the compound of formula II. In formula II the a particular embodiment of Hy as defined above and in claim 1, wherein there are two nitrogen atoms which are termed a first nitrogen and a second nitrogen. The first nitrogen is defined as the nitrogen attached to the phenyl ring having substituents R ¹ -R ⁵ of formula II and the second nitrogen is defined as the nitrogen attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula II. Consequently, in this particular embodiment of Hy one nitrogen of either the monoheterocyclic ring, the biheterocyclic group, the spiroheterocyclic group or the first and second monoheterocyclic ring connected by a linker, such as a bond, is attached to the phenyl ring having substituents R ¹ -R ⁵ of formula II and the second nitrogen of either the monoheterocyclic ring, the biheterocyclic group, the spiroheterocyclic group or the first and second monoheterocyclic ring connected by a linker, such as a bond, is attached to the carbon atom linked to R ⁶ and CH ₂ -X-R ⁷ of formula II, and the first and second nitrogen cannot be the same obviously, however, the terminology first and second nitrogen should not be construed to mean that the above mentioned heterocyclic rings cannot contain additional nitrogens (N), oxygens (O), and/or sulphurs (S). The following table shows the IUPAC name of each compound and the corresponding chemical structure:

In a second aspect the present invention relates to a compound of any one of the above aspect or embodiments for use as a medicament and for use in a method for treating diabetes or pre-diabetes, in a subject in need thereof. Typically, the diabetes is type 2. In a preferred embodiment the compound of formula I or II binds to VDAC1 in an MST assay with a K _D value of less than 15 µM, or less than 10 µM, such as less than 5 µM, such as less than 1 µM. In a third aspect the present invention relates to a method for treating diabetes or pre-diabetes in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula I or II. In an embodiment treating diabetes or pre-diabetes comprises at least one of treating insulin resistance, such as insulin resistance in diabetes type 2; inducing glucose-stimulated insulin secretion; improving glucose tolerance; restoring insulin secretion from pancreatic β-cells of a subject affected with diabetes; and prevention of β-cell dysfunction. In a fourth aspect the present invention relates to a method for preventing the progress of diabetes and/or preventing progress of prediabetes to diabetes and/or reversal of diabetes and/or for reversal of diabetes due to reversal of beta cell dysfunction in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula I or II. The term “halogen” as used herein means Cl, F, I or Br. The term “quaternary ammonium” as used herein means a nitrogen having four valence bonds, such as NH ₄ ⁺ or N(CH ₃ ) ₄ ⁺ . The term “C _1-x alkyl” as used herein means a linear alkyl group containing 1- x carbon atoms, e.g. C _1-3 or C _1-6, such as methyl, ethyl, propyl, butyl, pentyl or hexyl. The term “C _5-7 cycloalkyl” as used herein means a cyclic alkyl group containing 5-7 carbon atoms, such as cyclopentyl, cyclohexyl, or cycloheptyl. The term “C _2-4 alkenyl” as used herein means means a linear alkenyl having from 2-4 carbonatoms and comprising one double bond, such as ethenyl. The term “Oxo” as used herein means an oxygen atom with double bonds, also indicated as =O. The term “COO-C _1-6 alkyl, SO ₃ -C _1-6 alkyl, NHCO-C _1-3 alkyl, OC _1-3 alkyl, SO ₂ - C _1-3 alkyl” as used herein means a group selected from COO, SO ₃ , NHCO, O, or SO ₂ to which is attached a C _1-x alkyl as defined above. The term “C1-3 alkyl-CN” as used herein means a C1-x alkyl as defined above having a CN attached to one of the carbon atoms. The term “aryl” as used herein means a mono or bicyclic aromatic ring system containing 6-12 carbon atoms, such as phenyl or naphthyl. The term “a monoheterocyclic ring” as used herein means one ring comprising carbon atoms and at least one hetero atom, such as N, O or S. The term “a biheterocyclic group” as used herein means two monoheterocyclic rings fused together and sharing two ring atoms, and each comprising carbon atoms and at least one hetero atom, such as N, O or S. The term “a non-aromatic heterocyclic system” as used herein in connection with a monoheterocyclic ring, a biheterocyclic group, a spiroheterocyclic group or a first and a second monoheterocyclic ring connected by a linker, such as a bond, means a saturated or partly unsaturated system, provide that none of the heterocyclic rings are aromatic. The term “VDAC” as used herein refers to Voltage-Dependent Anion Channel protein of a highly conserved family of mitochondrial porins. Three VDAC isoforms, VDAC Type 1 (VDAC1), VDAC Type 2 (VDAC2) and VDAC Type 3 (VDAC3), encoded by three genes, are known to date. As used herein the term “VDAC1” as mean mammalian VDAC1 and in particular human VDAC1 comprising 283 amino acids (NP_003365) (Shoshan-Barmatz V et al., 2010. Molecular aspects of medicine 31:227-285). When the compound of formula I or II and pharmaceutical compositions herein disclosed are used for the above treatment, a therapeutically effective amount of at least one compound is administered to a mammal in need of said treatment. The term “treatment” and “treating” as used herein means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. The treatment may either be performed in an acute or in a chronic way. The patient to be treated is preferably a mammal; in particular, a human being, but it may also include animals, such as dogs, cats, cows, sheep, pigs rats, mice, rabbits, guienna pigs. The term "a therapeutically effective amount" of the compound for use of the present invention as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective amount". Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary. In a still further aspect the present invention relates to a pharmaceutical composition comprising the compound of formula I or II and optionally a pharmaceutically acceptable additive, such as a carrier or an excipient. As used herein “pharmaceutically acceptable additive” is intended without limitation to include carriers, excipients, diluents, adjuvant, colorings, aroma, preservatives etc. that the skilled person would consider using when formulating a compound of the present invention in order to make a pharmaceutical composition. The adjuvants, diluents, excipients and/or carriers that may be used in the composition of the invention must be pharmaceutically acceptable in the sense of being compatible with the compound of formula I or II and the other ingredients of the pharmaceutical composition, and not deleterious to the recipient thereof. It is preferred that the compositions shall not contain any material that may cause an adverse reaction, such as an allergic reaction. The adjuvants, diluents, excipients and carriers that may be used in the pharmaceutical composition of the invention are well known to a person skilled within the art. As mentioned above, the compositions and particularly pharmaceutical compositions as herein disclosed may, in addition to the compounds of formula I or II herein disclosed, further comprise at least one pharmaceutically acceptable adjuvant, diluent, excipient and/or carrier. In some embodiments, the pharmaceutical compositions comprise from 1 to 99 % by weight of said at least one pharmaceutically acceptable adjuvant, diluent, excipient and/or carrier and from 1 to 99 % by weight of a compound of formula I or II as herein disclosed. The combined amount of the active ingredient and of the pharmaceutically acceptable adjuvant, diluent, excipient and/or carrier may not constitute more than 100% by weight of the composition, particularly the pharmaceutical composition. In some embodiments, only one compound of formula I or II as herein disclosed is used for the purposes discussed above. In some embodiments, two or more of the compounds of formula I or II as herein disclosed are used in combination for the purposes discussed above. The composition, particularly pharmaceutical composition comprising a compound set forth herein may be adapted for oral, intravenous, topical, intraperitoneal, nasal, buccal, sublingual, or subcutaneous administration, or for administration via the respiratory tract in the form of, for example, an aerosol or an air-suspended fine powder. Therefore, the pharmaceutical composition may be in the form of, for example, tablets, capsules, powders, nanoparticles, crystals, amorphous substances, solutions, transdermal patches or suppositories. Further embodiments of the process are described in the experimental section herein, and each individual process as well as each starting material constitutes embodiments that may form part of embodiments. The above embodiments should be seen as referring to any one of the aspects (such as ‘method for treatment’, ‘pharmaceutical composition’, ‘compound of formula I or II for use as a medicament’, or ‘compound of formula I or II for use in a method’) described herein as well as any one of the embodiments described herein unless it is specified that an embodiment relates to a certain aspect or aspects of the present invention. All references, including publications, patent applications and patents, cited herein are hereby incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein. All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way. Any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. The terms “a” and “an” and “the” and similar referents as used in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The term “and/or” as used herein is intended to mean both alternatives as well as each of the alternatives individually. For instance, expression “xxx and/or yyy” means “the xxx and yyy; the xxx; or the yyy”, all three alternatives are subject to individual embodiments. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless other-wise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. Unless otherwise stated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement can be considered to also pro-vide a corresponding approximate measurement, modified by "about," where appropriate). All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise indicated. No language in the specification should be construed as indicating any element is essential to the practice of the invention unless as much is explicitly stated. The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability and/or enforceability of such patent documents. The description herein of any aspect or embodiment of the invention using terms such as “comprising”, “having”, “including” or “containing” with reference to an element or elements is intended to provide support for a similar aspect or embodiment of the invention that “consists of”, “consists essentially of”, or “substantially comprises” that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context). This invention includes all modifications and equivalents of the subject matter recited in the aspects or claims presented herein to the maximum extent permitted by applicable law. The present invention is further illustrated by the following examples that, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realizing the invention in diverse forms thereof. MST assay and data MicroScale Thermophoresis (MST) is a biophysical technique that measures the strength of interaction (affinity) between two molecules by detecting variations in fluorescence signal as a result of an IR-laser induced temperature change. The range of the variation in the fluorescence signal correlates with the binding of a ligand to a fluorescent target. By that it allows for quantitative analysis of molecular interactions in solution on the microliter scale with high sensitivity.The MST signal is composed of two major factors: The TRIC effect and the thermophoresis. TRIC stands for Temperature-Related Intensity-Change and describes how the fluorescence intensity of a fluorophore depends on the local temperature of the solution. For the vast majority of fluorophores, the fluorescence intensity decreases with increasing temperature. Most importantly, however, the extent of the temperature dependence is strongly related to the chemical environment of the fluorophore. This environment is sensitively affected by the binding of a ligand molecule to the fluorescently labeled target molecule (via conformational changes or ligand-dye proximity). The second component of the MST-signal, the thermophoresis describes the movement of molecules along temperature gradients which results in a quantifiable change of the local concentration of the target molecules. As these target molecules are fluorescently labeled in MST, such concentration changes can be monitored simply by fluorescence measurements. This directed movement of molecules depends on their molecular size, charge, and hydration shell. Binding of a ligand to a target molecule leads to the change of at least one of these parameters and therefore to an altered thermophoretic movement of the target-ligand complex compared to the single molecules alone. In sum, both TRIC and thermophoresis contribute to the overall MST-signal, which is detected by fluorescence measurement. Due to this robust physical principle and direct monitoring, MST can be used for determining the affinity and binding strength of almost any kind of molecular interaction or modification of small molecules, proteins, peptides, DNA, sugars, or molecular complexes. For an in-depth description of the physical principles behind MST, reference is made to the following (Jerabek-Willemsen M, André T, Wanner A, Roth HM, Duhr S, Baaske P, Breitsprecher D (2014). "MicroScale Thermophoresis: Interaction analysis and beyond". Journal of Molecular Structure.1077: 101–113 and Jerabek- Willemsen M, Wienken CJ, Braun D, Baaske P, Duhr S (2011). "Molecular interaction studies using microscale thermophoresis". Assay and Drug Development Technologies.9 (4): 342–53. Recombinant VDAC1 labeling Reconstituted N-terminal His-GST tagged E. coli recombinant human VDAC1 (hVDAC1) was buffer exchanged into protein labeling buffer due to the primary amine of the Tris lyophilization buffer interferes with NHS-based labeling. The labeling buffer was kept as close to the storage buffer of the target protein as given on the protein data sheet (LSBio LS-G25810). Tris was replaced by HEPES. PLURONIC® F-127 was added to 0.05% in order to enhance protein recovery in the final dye removal step. The total volume of the labeling batch was 100 µL. The labeling time was 30 minutes. The labeling reaction was performed at room temperature. Any unbound or unreacted dye was separated from the labeled protein on a gravity-flow gel-filtration column (GE Healthcare, PD Minitrap G-25, GE28- 9180-07). The final target buffer was kept as close to the original protein storage buffer as possible. It contained Tris again instead of HEPES. Assay validation The first step of the technical assay establishment was a so-called “noise test”. In this test, the intrinsic MST-noise of the labeled target protein was tested. Subsequently, a reference compound or positive control (CAS number: 2086257-77- 2) was characterized to confirm previously reported VDAC1 binding (Zhang et al (2019)). Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in ^ Cells”. Cell Metabolism 29, 64–77.). In short, serial dilutions of the compound having CAS number: 2086257-77-2 was prepared in a way to match the final buffer conditions in the reaction mix (assay buffer). The highest concentration of ligand was 10.0 mM and the lowest 4.88 μM. A total of 12 dilution steps were prepared. The serial dilution was prepared in a total volume of 10 µL for each step with 0.1 μl of each dilution step mixed with 9.9 μl of the fluorescent target molecule (labeled VDAC1). The final reaction mixture, which was filled into premium-coated MST capillaries, contained a respective amount of ligand (max. conc.100 μM, min. conc.41 nM) and constant 5 nM fluorescent target molecule. The samples were analyzed on a NT.Automated instrument (Nanotemper Technologies, Munich) at 25°C, with 10% LED power and 40% Laser power. To test the reproducibility of the established positive control interaction was tested using labeled VDAC1 at 4 °C for 0, 2, 4, 6 hours before preparation of assay samples. Screening assay Compound serial dilutions were prepared using a Labcyte Echo 550 acoustic nano-liter dispenser.10 mM DMSO compound stocks were transferred to LabCyte LP-0200384-well plates (“source plates”). In 12 adjacent wells (e.g. A1-A12) of Greiner 784201384-well plates (“destination plates”), a serially reduced volume series of the compounds were dispensed: 100, 50, 25, 12.5, 7.5, 2.5, 1.56, 0.78, 0.41, 0.20, 0.08, 0.04 nL (volumes below 1 nL were dispensed from intermediate DMSO dilutions of the compounds). After that, a DMSO-backfill was performed by filling each well up to a total volume of 100 nL. The destination plates were sealed with a heat-seal and stored at room temperature until use. In addition to the compound serial dilutions, DMSO references were prepared in the same manner by dispensing a serially reduced volume series of DMSO (same volumes as above) and back-filling to 100 nL with DMSO. The high-throughput compound screening was performed as follows.100 µL labeled VDAC1 stock were thawed and centrifuged (15 min, 21000 x g, 4°C) and 90 µl supernatant was used. The thawed and centrifuged labeled VDAC1 stock was stored on ice for a maximum of 6 hours. After 6 hours, fresh labeled stock was thawed and centrifuged as described above. A positive control test with CAS number: 2086257-77-2 was prepared as described above. A positive control for assay validation was performed every 6 hours and after thawing a fresh labeled VDAC1 stock. A positive control was also performed after the full compound set had been measured. For compound Example 1-10 screening, the labeled VDAC1 stock was diluted to 5.05 nM in assay buffer (see Table 1) and added to the pre-dispensed compound plates.10 µL diluted VDAC1 stock were added per well using an Opentrons OT-2 liquid handling robot. Four 24-capillary chips (enough capillaries for 8 ligands in 12-data-point serial dilution) were filled with the sample solutions at a time (premium coated capillaries, Nanotemper Technologies, Munich, Germany). Filled capillaries were incubated for 10 minutes at room temperature. Four capillary chips (total of 8 ligands in serial dilution) were loaded into an NT.Automated MST instrument (Nanotemper Technologies, Munich, Germany) and measured with the settings listed in Table 1. The 12 p-data-point DMSO references were analyzed similarly. Table 1: HTS-MST assay parameters

Data analysis The tested ligand compounds were classified into the following categories; binder, weak binder and non-binder. Data were analyzed with MO.AffinityAnalysis (version 2.2.6.5385, Nanotemper Technologies, Munich, Germany) and MO.ScreeningAnalysis (version 1.0.2.8057, Nanotemper Technologies, Munich, Germany). MST traces (fluorescence vs. time) were analyzed at the time intervals -3 to 0 seconds (laser off, “cold” time interval) and +1.5 to +2.5 seconds (laser on, “hot” time interval). Fnorm data were fitted to the KD model. For classifying the analyzed ligands into the pre-defined categories, a 12-point DMSO blank-control was included in the screen. The noise of this blank control was 1.35 Fnorm units (2∙STDE(Fnorm)). Thus, for a classification as binder or weak binder, a minimum Fnorm signal amplitude of >(2∙noise) (> 2.7) was required. A typical MST plot of Example 4 is shown in Figure 1. (The MST plot is of the compound of Example 4; K _D 5.1 µM (S/N 20.1; dFnorm 23.9). EXAMPLES Abbreviatons used: DCM Dichloromethane TFA Trifluoroacetic acid CDI Carbonyldiimidazole MeCN Acetonitrile HOAc Acetic acid MeOH Methanol NaBH ₃ CN Sodium cyanoborohydride NBS 1-Bromo-2,5-pyrrolidinedione K ₂ CO ₃ Potassium carbonate DIPEA N,N-Diisopropylethylamine HATU 1-[Bis(dimethylamino)methylene]-1H- 1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate DMF Dimethylformamide NaOH Sodium hydroxide THF Tetrahydrofuran LiHMDS Lithium bis(trimethylsilyl)amide DIAD Diisopropyl azodicarboxylate PPh ₃ Triphenylphosphine r.t. Room temperature 1. HPLC purification Purification was performed by HPLC (H ₂ O – MeOH; Agilent 1260 Infinity systems equipped with DAD and mass-detectors. Waters Sunfire C18 OBD Prep Column, 100Å, 5 µm, 19 mm X 100 mm with SunFire C18 Prep Guard Cartridge, 100Å, 10 µm, 19 mm X 10 mm). The material was dissolved in 0.7 mL DMSO. Flow: 30mL/min. Purity of the obtained fractions was checked via the analytical LCMS. Spectra were recorded for each fraction as it was obtained straight after chromatography in the solution form. The solvent was evaporated in the flow of N ₂ at 80°C. On the basis of post-chromatography LCMS analysis fractions were united. Solid fractions were dissolved in 0.5 mL MeOH and transferred into a pre-weighted marked vial. Obtained solutions were again evaporated in the flow of N ₂ at 80°C. After drying, products were finally characterized by LCMS and ¹ H NMR. 2. Analytical Methods NMR Instrument specifications: Bruker AVANCE DRX 500 Varian UNITYplus 400 LC/MS Instrument specifications: Agilent 1100 Series LC/MSD system with DAD\ELSD and Agilent LC\MSD VL (G1956A), SL (G1956B) mass-spectrometer. Agilent 1200 Series LC/MSD system with DAD\ELSD and Agilent LC\MSD SL (G6130A), SL (G6140A) mass-spectrometer. All the LC/MS data were obtained using positive/negative mode switching. Column Zorbax SB-C181.8 µm 4.6 x 15mm Rapid Resolution cartridge (PN 821975- 932) Mobile phase А – acetonitrile, 0.1% formic acid В – water (0.1% formic acid) Flow rate 3 ml/min Gradient 0 min – 100% B 0.01 min – 100% B 1.5 min - 0% B 1.8 min - 0% B 1.81 min - 100% B Injection volume 1 µl Ionization mode atmospheric pressure chemical ionization (APCI) Scan range m/z 80-1000 3. Experimental All compounds were isolated as racemates if not otherwise stated. Synthesis of 4-chloro-N-(3-hydroxy-2-{4-[4-(trifluoromethoxy)phenyl]piper azin- 1-yl}propyl)benzamide Example 1 Step 1: Synthesis of 4-chloro-N-(prop-2-en-1-yl)benzamide Prop-2-en-1-amine (1.48 g, 25.97 mmol) was dissolved in CH ₂ Cl ₂ (30 mL). 4- Chlorobenzoyl chloride (5.0 g, 28.57 mmol) and triethylamine (5.78 g, 57.13 mmol) were added and the mixture was stirred for 2 days at room temperature under nitrogen. Then, aqueous NaOH solution (1 M, 30 mL) was added, and the mixture was extracted with CH ₂ Cl ₂ (2 × 30 mL). The organic layers were combined and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by flash chromatography (5:1 hexane/EtOAc, R _f = 0.10) to provide 4- chloro-N-(prop-2-en-1-yl)benzamide (4.46 g, 22.8 mmol, 87.8% yield) as a yellow solid. To a stirred solution of the 4-chloro-N-(prop-2-en-1-yl)benzamide (4.4 g, 22.49 mmol) in 2:1 acetonitrile/water solution (100 mL:50 mL) 4-methylmorpholin-4-ium- 4-olate (5.27 g, 44.98 mmol) was added at 0 ^o C followed by tetraoxoosmium (114.35 mg, 449.79 µmol). The mixture was stirred overnight at room temperature; The reaction was quenched by the addition of sodium sulfite (25 g) and diluted with water (60 mL). The aqueous solution was then extracted with EtOAc (3 × 90 mL), the combined organic extracts were dried over sodium sulfate and concentrated in vacuo to afford 4-chloro-N-(2,3-dihydroxypropyl)benzamide (4.45 g, 19.38 mmol, 86.2% yield) as crystalline solid. 4-Chloro-N-(2,3-dihydroxypropyl)benzamide (3.92 g, 17.07 mmol) was suspended in CH ₂ Cl ₂ (600 mL). Tert-butyl(chloro)dimethylsilane (2.86 g, 18.95 mmol) in CH ₂ Cl ₂ (10 mL) was added under stirring, followed by triethylamine (2.07 g, 20.48 mmol) and N,N-dimethylpyridin-4-amine (83.41 mg, 682.71 µmol). The mixture was stirred for 36 hours and was then shaken with water (100 mL). The aqueous phase was washed with CH ₂ Cl ₂ (70 mL), and the combined organic phases was combined, washed with brine (2 × 50 mL) and then dried over Na ₂ SO ₄ . The solution was concentrated under reduced pressure, and the oily residue was purified by chromatography on silica gel (hexane/EtOAc 1/1, R _f = 0.42) to afford N-3-[(tert- butyldimethylsilyl)oxy]-2-hydroxypropyl-4-chlorobenzamide (2.61 g, 7.59 mmol, 44.5% yield) as colorless oil. To a solution of 1,1,1-tris(acetoxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one (493.73 mg, 1.16 mmol) in anhydrous dichloromethane (5 mL) at room temperature was added a solution N-3-[(tert-butyldimethylsilyl)oxy]-2-hydroxypropyl-4- chlorobenzamide (400.35 mg, 1.16 mmol) in anhydrous dichloromethane (5 mL). The resulting mixture was stirred at room temperature for 12 h, then evaporated in vacuo to a third of the initial volume, and applied to a column packed with silica. Elution with ethyl acetate-petroleum ether solvent mixture (1/1) afforded N-3-[(tert- butyldimethylsilyl)oxy]-2-oxopropyl-4-chlorobenzamide (400.0 mg, 1.17 mmol, 100.5% yield) as colorless oil. 1-[4-(Trifluoromethoxy)phenyl]piperazine (345.89 mg, 1.4 mmol) was added to a solution of N-3-[(tert-butyldimethylsilyl)oxy]-2-oxopropyl-4-chlorobenza mide (400.24 mg, 1.17 mmol) in MeOH (10 mL) and the reaction mixture stirred at room temperature for 15 min, then sodium cyanoborohydride (73.56 mg, 1.17 mmol) was added and stirring continued for 48 h, then the solution was concentrated under reduced pressure to dryness. The residue was dissolved in CH ₂ Cl ₂ (10 mL) and 10% HCl (10 mL) was added, and the mixture stirred at room temperature for 2 hours, CH ₂ Cl ₂ was separated and the aqueous layer was washed CH ₂ Cl ₂ (10 mL). Organic layers were combined, aqueous layer was triturated with solid NaHCO ₃ to pH = 8. The crude product was extracted with CH ₂ Cl ₂ (3 × 15 mL). The organic layers were combined, dried under Na ₂ SO ₄ and concentrated under reduced pressure. The residue was purified by reverse preparative HPLC to afford 4-chloro-N-(3-hydroxy-2-4-[4- (trifluoromethoxy)phenyl]piperazin-1-ylpropyl)benzamide (29.0 mg, 63.34 µmol, 5.4% yield). LC-MS (ESI-pos): [M+H] ⁺ = 458.2/460.2 Synthesis of N-(4-chlorophenyl)-5-hydroxy-3-{4-[4- (trifluoromethoxy)phenyl]piperazin-1-yl}pentanamide Example 2 To a stirred suspension of sodium hydride (420.47 mg, 17.52 mmol) in THF (30 mL) was added ethyl 2-(diethyl phosphono)acetate (3.93 g, 17.52 mmol) at 0°C. The reaction mixture was stirred for 15 min, and a solution of the 3-(allyloxy)propanal (2.0 g, 17.52 mmol) in THF (5 mL) was then added. The mixture was stirred overnight at room temperature and then THF solution was evaporated in vacuo to afford ethyl (2E)-5-(prop-2-en-1-yloxy)pent-2-enoate (3.1 g, 16.83 mmol, 96% yield) as colorless oil. It was used in the next step without further purification. To a solution of 1-bromo-4-(trifluoromethoxy)benzene (24.1 g, 100.0 mmol) in toluene (500 mL) tert-butyl piperazine-1-carboxylate (16.76 g, 90.0 mmol), tris((4E)- 1,5-diphenylpenta-1,4-dien-3-one) dipalladium (2.29 g, 2.5 mmol), 1-[2- (diphenylphosphanyl)naphthalen-1-yl]naphthalen-2-yldiphenylp hosphane (3.11 g, 5.0 mmol) and sodium tert-butoxide (19.22 g, 200.0 mmol) were added consiquently. The mixture was refluxed under Ar atmosphere overnight. The solvent was evaporated to provide crude tert-butyl 4-[4-(trifluoromethoxy)phenyl]piperazine-1- carboxylate (63.0 g, 181.9 mmol, 181.9% yield) as a residue. It was directly used for next step without further purification.

To a solution of ethyl (2E)-5-(prop-2-en-1-yloxy)pent-2-enoate (2.0 g, 10.86 mmol) in dry MeOH (10 mL) was added 1-[4-(trifluoromethoxy)phenyl]piperazine (2.67 g, 10.86 mmol) and the reaction mixture was stirred at room temperature overnight, then 6 hours at reflux. The reaction mixture was evaporated and crude product purified by flash chromatography on silica (eluent DCM/EtOAC = 1/1, Rf = 0.65) to afford ethyl 5-(prop-2-en-1-yloxy)-3-4-[4-(trifluoromethoxy)phenyl]pipera zin-1- ylpentanoate (2.9 g, 6.74 mmol, 62.1% yield) . It was used in the next step without further purification. To a suspension of ethyl 5-(prop-2-en-1-yloxy)-3-4-[4- (trifluoromethoxy)phenyl]piperazin-1-ylpentanoate (2.9 g, 6.74 mmol) in MeOH and water (60 ml, 4/1) was added solution of sodium hydroxide (480.0 mg, 12.0 mmol) in water (3 mL) and reaction mixture stirred at room temperature 2 hours, then sodium hydrogen sulfate (1.52 g, 12.67 mmol) was added and reaction mixture stirred for 1 hour, and evaporated to dryness. The crude product was dissolved in MTBE (100 mL), washed with water (3x25), and evaporated to afford of 5-(prop-2- en-1-yloxy)-3-4-[4-(trifluoromethoxy)phenyl]piperazin-1-ylpe ntanoic acid (2.2 g, 5.47 mmol, 81.2% yield) as yellow oil, which was used in next without purification. To a stirred solution of 5-(prop-2-en-1-yloxy)-3-4-[4- (trifluoromethoxy)phenyl]piperazin-1-ylpentanoic acid (2.2 g, 5.47 mmol) in DCM (30 mL) was added dropwise oxalyl chloride (693.93 mg, 5.47 mmol) and reaction mixture stirred at room temperature for 1 hour. After this time reaction mixture evaporated, residue was dissolved in DCM (30 mL) then 4-chloroaniline (697.46 mg, 5.47 mmol) and triethylamine (1.38 g, 13.67 mmol, 1.91 ml) were added and stirring continued at room temperature for 2 hours. Reaction mixture washed of water (3×30 mL) and evaporated. The crude product was purified by column chromatography (silica, eluent hexane/EtOAc = 1/1, R _f = 0.36) to afford crude N-(4-chlorophenyl)-5- (prop-2-en-1-yloxy)-3-4-[4-(trifluoromethoxy)phenyl]piperazi n-1-ylpentanamide (1.21 g, 2.36 mmol, 43.2% yield) as a yellow oil. The crude material was further purified by reverse phase HPLC to afford pure title compound.

A mixture of N-(4-chlorophenyl)-5-(prop-2-en-1-yloxy)-3-4-[4- (trifluoromethoxy)phenyl]piperazin-1-ylpentanamide (511.0 mg, 998.12 µmol) , 1,3- dimethyl-1,3-diazinane-2,4,6-trione (314.48 mg, 2.01 mmol), tetrakis(triphenylphosphine)palladium(0) (57.76 mg, 49.81 µmol) and dry THF (4 mL) was heated at 90 °C in a sealed tube under argon atmosphere. After being stirred at the same temperature for 24 h, the reaction mixture was poured into sat. aq Na2CO3 and extracted with EtOAc twice. Organic layer was washed with brine, dried over MgSO ₄ and evaporated in vacuo. The crude product was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-5-hydroxy-3-4-[4- (trifluoromethoxy)phenyl]piperazin-1-ylpentanamide (151.9 mg, 321.89 µmol, 32 % yield). LC-MS (ESI-pos): [M+H] ⁺ = 472.2/474.2 Starting material synthesis In the examples below the p-trifluoromethoxyphenylaminoyl starting materials were synthesized from commercially available 1-bromo-4- (trifluoromethoxy)benzene and relevant amine by a method similarly to that described in Example 2, step 1B. The relevant amine may be protected by a cleavable protecting group such as e.g. a tert-butyloxycarbamoyl, a benzyloxycarbonyl group or similar. Alternatively, the p- trifluoromethoxyphenylaminoyl starting materials were synthesized from commercially available 1-bromo-4-(trifluoromethoxy)benzene and relevant non- protected amine by a method similarly to that described in Example 2, step 1B after which the starting materials were purified by standard methods known to a person skilled in the art, such as manual or automated silica chromatography. The Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{4-[4- (trifluoromethoxy)phenyl]-1,4-diazepan-1-yl}butanamide Example 3 Step 1: Synthesis of 4-{4-[4-(trifluoromethoxy)phenyl]-1,4-diazepan-1-yl}oxolan-2 - one A mixture of 1-[4-(trifluoromethoxy)phenyl]-1,4-diazepane (5.2 g, 19.98 mmol) and 2,5-dihydrofuran-2-one (3.36 g, 39.96 mmol) in MeOH (12.5 mL) was stirred at room temperature overnight. The mixture was evaporated in vacuo. The crude product was purified by column chromatography on silica gel (CH ₂ Cl _2/ EtOAc = 1/1, R _f = 0.12) to provide 4-4-[4-(trifluoromethoxy)phenyl]-1,4-diazepan-1-yloxolan-2- one (2.4 g, 6.97 mmol, 34.9% yield) as a yellow oil. Step 2: Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{4-[4- (trifluoromethoxy)phenyl]-1,4-diazepan-1-yl}butanamide

To a solution of 4-chloroaniline (254.87 mg, 2.0 mmol) in toluene (5 mL) was added trimethylaluminum (288.71 mg, 4.01 mmol). After stirring for 10 min, 4-4-[4- (trifluoromethoxy)phenyl]-1,4-diazepan-1-yloxolan-2-one (344.0 mg, 999.04 µmol) was added to a solution and the resulting mixture was heated to 80 ^o C for 8 hours. After cooling to room temperature, the solvent was evaporated in vacuo and the residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-4- hydroxy-3-4-[4-(trifluoromethoxy)phenyl]-1,4-diazepan-1-ylbu tanamide (38.6 mg, 81.8 µmol, 8% yield). LC-MS (ESI-pos): [M+H] ⁺ = 472.0/474.0 The Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{5-[4- (trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]py rrol-2- yl}butanamide Example 4 Step 1: Synthesis of tert-butyl 5-[4-(trifluoromethoxy)phenyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate tert-Butyl 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate hydrochloride (2.0 g, 8.11 mmol), tris(1,5-diphenylpenta-1,4-dien-3-one) dipalladium (206.2 mg, 225.18 µmol), 1-[2-(diphenylphosphanyl)naphthalen-1-yl]naphthalen-2- yldiphenylphosphane (280.43 mg, 450.37 µmol) and sodium tert-butoxide (2.6 g, 27.02 mmol) were added consequently to a solution of 1-bromo-4- (trifluoromethoxy)benzene (2.17 g, 9.01 mmol) in toluene (70 mL) The mixture was degassed twice and refluxed under Ar atmosphere overnight. The solvent was evaporated to provide crude tert-butyl 5-[4-(trifluoromethoxy)phenyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrole-2-carboxylate (7.2 g, 19.44 mmol) as a residue. It was directly used for next step without further purification. Step 2: Synthesis of 2-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H- pyrrolo[3,4-c]pyrrole A mixture of crude tert-butyl 5-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H- pyrrolo[3,4-c]pyrrole-2-carboxylate (3.34 g, 9.01 mmol) (obtained in previous step) in 45 mL of conc. HCl and 30 mL of DCM was stirred for 1.5 h at room temperature. After phase separation the DCM phase was discarded, and Na ₂ CO ₃ was added to the aqueous phase to pH ~9. Then 50 mL DCM were added then stirred for additional 0.5 h. The DCM phase was collected, dried over Na ₂ SO ₄ and concentrated in vacuo to provide 2-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4 - c]pyrrole (1.4 g, 5.18 mmol, 57.5% yield) as a white solid. Step 3: Synthesis of 4-{5-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H- pyrrolo[3,4-c]pyrrol-2-yl}oxolan-2-one A mixture of 2-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4 - c]pyrrole (1.4 g, 5.18 mmol) and 2,5-dihydrofuran-2-one (871.29 mg, 10.36 mmol) in MeOH (3.1 mL) was stirred at room temperature overnight The mixture was evaporated in vacuo, residue treated with water (20 mL), filtered, washed with water (2 × 20 mL), hexane (30 mL) and dried to afford 4-5-[4-(trifluoromethoxy)phenyl]- 1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yloxolan-2-one (1.6 g, 4.52 mmol, 87.1% yield) as a yellow solid . Step 4: The synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{5-[4- (trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]py rrol-2- yl}butanamide To a solution of 4-chloroaniline (254.67 mg, 2.0 mmol) in benzene (8 mL) was added trimethylaluminum (287.8 mg, 3.99 mmol). After stirring for 10 min, 4-5-[4- (trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]py rrol-2-yloxolan- 2-one (354.0 mg, 999.09 µmol) was added to a solution and the resulting mixture was heated to 50 ^o C for 2.5 hours. After cooling to room temperature, water (3 mL) and EtOAc (15 mL) was added, filtered and the solvent was evaporated in vacuo , the residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)- 4-hydroxy-3-5-[4-(trifluoromethoxy)phenyl]-1H,2H,3H,4H,5H,6H -pyrrolo[3,4- c]pyrrol-2-ylbutanamide (186.0 mg, 385.98 µmol, 38% yield). LC-MS (ESI-pos): [M+H] ⁺ = 482.2/484.0 In a similar manner to the synthesis of Example 5 step 4 was synthesized (Example 29 to 34, 36-37, 42, 44) Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{2-[4-(trifluoromethoxy)pheny l]-6- oxa-2,9-diazaspiro[4.5]decan-9-yl}butanamide Example 5 Step 1: Synthesis of tert-butyl 2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9- diazaspiro[4.5]decane-9-carboxylate tert-Butyl 6-oxa-2,9-diazaspiro[4.5]decane-9-carboxylate (2.5 g, 10.32 mmol), tris(1,5-diphenylpenta-1,4-dien-3-one) dipalladium (262.43 mg, 286.59 µmol), 1-[2- (diphenylphosphanyl)naphthalen-1-yl]naphthalen-2-yldiphenylp hosphane (356.9 mg, 573.17 µmol) and sodium tert-butoxide (2.2 g, 22.93 mmol) were added consequently to a solution of 1-bromo-4-(trifluoromethoxy)benzene (2.76 g, 11.46 mmol) in toluene (55 mL). The mixture was refluxed under Ar atmosphere overnight. The solvent was evaporated to provide crude tert-butyl 2-[4- (trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]decane-9- carboxylate (7.1 g, 17.64 mmol,) as a residue. It was used for next step without ANY purification. Step 2: Synthesis of 2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9- diazaspiro[4.5]decane A solution of the crude tert-butyl 2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9- diazaspiro[4.5]decane-9-carboxylate (4.61 g, 11.46 mmol) (obtained in previous step) in 45 mL of conc. HCl and 30 mL of DCM was stirred for 1.5 h at room temperature. After phase separation the DCM phase was discarded, and the aqueous phase was evaporated in vacuo to dryness. The residue was dissolved in a mixture of 20 mL NaOH (2.0 M). Then DCM (50 mL) was add and the mixture was stirred for additional 0.5 h. The DCM phase was collected, dried over Na ₂ SO ₄ and concentrated in vacuo to provide 2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]deca ne (2.3 g, 7.61 mmol, 66.4% yield) as yellow oil. Step 3: Synthesis of 4-{2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9- diazaspiro[4.5]decan-9-yl}oxolan-2-one A mixture of 2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]deca ne (999.91 mg, 3.31 mmol) and 2,5-dihydrofuran-2-one (556.19 mg, 6.62 mmol) in MeOH (2.0 ml ) was stirred at room temperature overnight. The mixture was evaporated in vacuo, the residue was dissolved in MTBE (50 mL), washed with water (2 × 50 mL), brine (30 mL) and evaporated to afford 4-2-[4- (trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]decan-9-y loxolan-2-one (920.0 mg, 2.38 mmol, 72% yield) as a brown oil. Step 4: Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{2-[4- (trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]decan-9-y l}butanamide To a solution of 4-chloroaniline (255.57 mg, 2.0 mmol) in benzene (8 mL) was added trimethylaluminum (288.82 mg, 4.01 mmol, 2.0 ml). After stirring for 10 min, 4-2- [4-(trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]decan- 9-yloxolan-2-one (387.0 mg, 1.0 mmol) was added to a solution and the resulting mixture was heated to 50 ^o C for 2.5 hours. After cooling to room temperature, water (3 mL) and EtOAc (15 mL) was added, filtered and the solvent was evaporated in vacuo , the residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-4-hydroxy- 3-2-[4-(trifluoromethoxy)phenyl]-6-oxa-2,9-diazaspiro[4.5]de can-9-ylbutanamide (184.0 mg, 358.02 µmol, 35.7% yield). LC-MS (ESI-pos): [M+H] ⁺ = 514.2/516.0. In a similar manner to the synthesis of Example 5 step 4 was synthesized (Example 11 to 28, 35, 38 to 41, 43) Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-(3-{1-[4- (trifluoromethoxy)phenyl]azetidin-3-yl}piperidin-1-yl)butana mide Example 6 Step 1: Synthesis of 3-{1-[4-(trifluoromethoxy)phenyl]azetidin-3-yl}piperidine Benzyl 3-1-[4-(trifluoromethoxy)phenyl]azetidin-3-ylpiperidine-1-ca rboxylate (4.2 g, 9.67 mmol) was dissolved in MeOH (50 mL), 10% Pd/C (300 mg) was added and the reaction mixture was stirred overnight under H ₂ atmosphere. The reaction mixture was filtered and evaporated under reduced pressure; the residue was treated with 10 N HCl (30 mL) and DCM (30 mL). Organic layer was diluted, aqueous layer was washed DCM (2x20 mL), and added 6N NaOH to pH ~10, the crude product was extracted with DCM (3 × 40 mL), organic layers were combined, dried over Na ₂ SO ₄ and concentrated under reduced pressure to afford 3-1-[4- (trifluoromethoxy)phenyl]azetidin-3-ylpiperidine (800.0 mg, 2.66 mmol, 27.6% yield) as a brown oil. Step 2: Synthesis of 4-(3-{1-[4-(trifluoromethoxy)phenyl]azetidin-3-yl}piperidin- 1- yl)oxolan-2-one A mixture of 3-1-[4-(trifluoromethoxy)phenyl]azetidin-3-ylpiperidine (800.03 mg, 2.66 mmol) and 2,5-dihydrofuran-2-one (447.93 mg, 5.33 mmol) in MeOH (1.6 ml ) was stirred at room temperature overnight The mixture was evaporated in vacuo,the residue was dissolved in MTBE (50 mL), washed with water (2x50 mL), brine (30 mL) and evaporated to afford 4-(3-1-[4-(trifluoromethoxy)phenyl]azetidin-3- ylpiperidin-1-yl)oxolan-2-one (600.0 mg, 1.56 mmol, 58.6% yield, purity ~85%, mixture of diastereomers). Step 3: Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-(3-{1-[4- (trifluoromethoxy)phenyl]azetidin-3-yl}piperidin-1-yl)butana mide To a solution of 4-chloroaniline (398.69 mg, 3.13 mmol) in benzene (15 mL) was added trimethylaluminum ( g, mol) . After stirring for 10 min, 4-(3-1-[4- (trifluoromethoxy)phenyl]azetidin-3-ylpiperidin-1-yl)oxolan- 2-one (600.0 mg, 1.56 mmol) was added to a solution and the resulting mixture was heated to 50 ^o C for 2.5 hours. After cooling to room temperature, water (3 mL) and EtOAc (15 mL) was added, filtered and the solvent was evaporated in vacuo, the residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-4-hydroxy-3-(3-1-[4- (trifluoromethoxy)phenyl]azetidin-3-ylpiperidin-1-yl)butanam ide (23.0 mg, 44.93 µmol, 3% yield). LC-MS (ESI-pos): [M+H] ⁺ = 512.2/514.2 Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{6-[4-(trifluoromethoxy)pheny l]- 2,6-diazaspiro[3.4]octan-2-yl}butanamide Example 7 Step 1: Synthesis of 4-{6-[4-(trifluoromethoxy)phenyl]-2,6-diazaspiro[3.4]octan-2 - yl}oxolan-2-one A mixture of 6-[4-(trifluoromethoxy)phenyl]-2,6-diazaspiro[3.4]octane (1.6 g, 5.88 mmol) and 2,5-dihydrofuran-2-one (1.24 g, 14.69 mmol) in 10 ml of EtOH was stirred at room temperature for 16 hours and concentrated under reduced pressure. A residue was dissolved in 50 ml of MTBE, washed with water (3 × 50 mL), brine (50 mL) and dried over sodium sulfate. The filtrate was concentrated under reduced pressure to afford 4-6-[4-(trifluoromethoxy)phenyl]-2,6-diazaspiro[3.4]octan-2- yloxolan-2-one (800.0 mg, 75.0% purity, 1.68 mmol, 28.7% yield) as a yellow solid which was used without purification. Step 2: Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{6-[4- (trifluoromethoxy)phenyl]-2,6-diazaspiro[3.4]octan-2-yl}buta namide Trimethylaluminum (504.74 mg, 7.0 mmol, 3.5 ml) was added dropwise to a stirred solution of 4-chloroaniline (446.62 mg, 3.5 mmol) in 8 mL of benzene under argon. After 10 min of stirring 4-6-[4-(trifluoromethoxy)phenyl]-2,6-diazaspiro[3.4]octan- 2-yloxolan-2-one (800.0 mg, 2.25 mmol) in 2 ml of benzene was added to the reaction dropwise and the mixture was stirred at 50 °C for 2 hours. The mixture was quenched with water (10 mL). The resulting slurry was diluted with EtOAc (40mL) and stirred rigorously for 15 min. Organic layer was separated, washed with brine, dried over sodium sulfate and concentrated under reduced pressure. A residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-4-hydroxy-3-6- [4-(trifluoromethoxy)phenyl]-2,6-diazaspiro[3.4]octan-2-ylbu tanamide (150.0 mg, 95.0% purity, 294.48 µmol, 13.1% yield). LC-MS (ESI-pos): [M+H] ⁺ = 484.2 / 486.2 Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{1-[4-(trifluoromethoxy)pheny l]- octahydro-1H-pyrrolo[3,2-b]pyridin-4-yl}butanamide Example 8 Step 1: Synthesis of 4-{1-[4-(trifluoromethoxy)phenyl]-octahydro-1H-pyrrolo[3,2- b]pyridin-4-yl}oxolan-2-one A mixture of 1-[4-(trifluoromethoxy)phenyl]-octahydro-1H-pyrrolo[3,2-b]py ridine (500.44 mg, 1.75 mmol) and 2,5-dihydrofuran-2-one (367.38 mg, 4.37 mmol, 310.0 µL) in 10 mL of EtOH was stirred at room temperature for 16 hours and concentrated under reduced pressure. A residue was dissolved in 80 mL of MTBE, washed with water (3 × 50 mL), brine (50 mL) and dried over sodium sulfate. The filtrate was concentrated under reduced pressure to afford 4-1-[4-(trifluoromethoxy)phenyl]- octahydro-1H-pyrrolo[3,2-b]pyridin-4-yloxolan-2-one (400.0 mg, 64.0% purity, 691.21 µmol, 39.5% yield) as a mixture of diastereomers which was used for the next step without purification. Step 2: Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{1-[4- (trifluoromethoxy)phenyl]-octahydro-1H-pyrrolo[3,2-b]pyridin -4-yl}butanamide Trimethylaluminum (311.54 mg, 4.32 mmol, 2.16 mL) was added dropwise to a stirred solution of 4-chloroaniline (275.67 mg, 2.16 mmol) in 4 mL of benzene under argon. After 10 min of stirring 4-1-[4-(trifluoromethoxy)phenyl]-octahydro-1H- pyrrolo[3,2-b]pyridin-4-yloxolan-2-one (400.0 mg, 1.08 mmol) in 1 mL of benzene was added dropwise and the mixture was stirred at 50 °C for 2 hours. The mixture was quenched with water (10 mL). The resulting slurry was diluted with EtOAc (40 mL) and stirred rigorously for 15 min. Organic layer was separated, washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-4- hydroxy-3-1-[4-(trifluoromethoxy)phenyl]-octahydro-1H-pyrrol o[3,2-b]pyridin-4- ylbutanamide (77.0 mg, 154.64 µmol, 14.3% yield). LC-MS (ESI-pos): [M+H] ⁺ = 498.2 / 500.2 Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{5-[4-(trifluoromethoxy)pheny l]- octahydropyrrolo[3,4-c]pyrrol-2-yl}butanamide Example 9 Step 1: Synthesis of tert-butyl 5-[4-(trifluoromethoxy)phenyl]- octahydropyrrolo[3,4-c]pyrrole-2-carboxylate tert-butyl octahydropyrrolo[3,4-c]pyrrole-2-carboxylate (2.0 g, 9.42 mmol), tris(1,5- diphenylpenta-1,4-dien-3-one) dipalladium (239.64 mg, 261.69 µmol), 1-[2- (diphenylphosphanyl)naphthalen-1-yl]naphthalen-2-yldiphenylp hosphane (325.9 mg, 523.39 µmol) and sodium tert-butoxide (2.01 g, 20.94 mmol) were added consequently to a solution of 1-bromo-4-(trifluoromethoxy)benzene (2.52 g, 10.47 mmol) in toluene (50 mL). The mixture was refluxed under argon overnight. The solvent was evaporated to provide crude tert-butyl 5-[4-(trifluoromethoxy)phenyl]- octahydropyrrolo[3,4-c]pyrrole-2-carboxylate (3.9g). It was used for next step without any purification. Step 2: Synthesis of 2-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3,4- c]pyrrole Crude tert-butyl 5-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3,4-c]pyrrol e-2- carboxylate (3.9 g, 10.47 mmol) was dissolved in DCM (50 mL) and 50 mL of conc HCl was added slowly. The mixture was stirred at rt for 2 hours. Layers were separated; aqueous layer was washed with DCM (2 × 50 mL) and concentrated under reduced pressure. A residue was dissolved in 30 mL of water and basified with NaHCO ₃ . A resulting slurry was extracted with DCM (2 × 50 mL), organic phase was washed with brine, dried over Na ₂ SO ₄ and concentrated under reduced pressure to afford 2-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3,4-c]pyrrol e (1.1 g, 3.84 mmol, 36.7% yield). Step 3: Synthesis of 4-{5-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3,4- c]pyrrol-2-yl}oxolan-2-one A mixture of 2-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3,4-c]pyrrol e (1.1 g, 4.04 mmol) and 2,5-dihydrofuran-2-one (1.02 g, 12.12 mmol) in 10 mL of EtOH was stirred at room temperature for 16 hours and concentrated under reduced pressure. A residue was dissolved in 80 mL of MTBE, washed with water (3 × 50 mL), brine (50 mL) and dried over sodium sulfate. The filtrate was concentrated under reduced pressure to afford 4-5-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3,4-c]pyrr ol- 2-yloxolan-2-one (750.0 mg, 87.0% purity, 1.83 mmol, 45.3% yield) as a brown oil which was used without purification. Step 4: Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{5-[4- (trifluoromethoxy)phenyl]-octahydropyrrolo[3,4-c]pyrrol-2-yl }butanamide Trimethylaluminum (510.0 mg, 7.07 mmol, 3.54 ml) was added dropwise to a stirred solution of 4-chloroaniline (452.65 mg, 3.55 mmol) in 8 mL of benzene under argon. After 10 min of stirring 4-5-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3,4- c]pyrrol-2-yloxolan-2-one (754.78 mg, 2.12 mmol) in 2 mL of benzene was added to the reaction dropwise and the mixture was stirred at 50 °C for 2 hours. The mixture was quenched with water (10 mL). The resulting slurry was diluted with EtOAc (40 mL) and stirred rigorously for 15 min. Organic layer was separated, washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-4- hydroxy-3-5-[4-(trifluoromethoxy)phenyl]-octahydropyrrolo[3, 4-c]pyrrol-2- ylbutanamide (330.0 mg, 99.0% purity, 675.12 µmol, 31.9% yield). LC-MS (ESI- pos): [M+H] ⁺ = 484.2 / 486.2 Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{8-[4-(trifluoromethoxy)pheny l]- 2,8-diazaspiro[5.5]undecan-2-yl}butanamide Example 10 Step 1: Synthesis of 2-[4-(trifluoromethoxy)phenyl]-2,8-diazaspiro[5.5]undecane 2,8-Diazaspiro[5.5]undecane (2.0 g, 12.97 mmol), tris(1,5-diphenylpenta-1,4-dien- 3-one) dipalladium (296.84 mg, 324.17 µmol), 1-[2- (diphenylphosphanyl)naphthalen-1-yl]naphthalen-2-yldiphenylp hosphane (403.7 mg, 648.33 µmol) and sodium tert-butoxide (2.49 g, 25.93 mmol) were added consequently to a solution of 1-bromo-4-(trifluoromethoxy)benzene (2.5 g, 10.37 mmol) in toluene (60 mL). The mixture was refluxed under Ar atmosphere overnight. The solvent was evaporated and the residue was treated a 45 mL of conc. HCl and 30 mL of DCM, then was stirred for 1.5 h at room temperature. After phase separation the DCM phase was discarded, and the aqueous phase was evaporated in vacuo to dryness. The residue was dissolved in 20 mL NaOH (2.0 M). Then DCM (50 mL) was added and the mixture was stirred for additional 0.5 h. The DCM phase was collected, dried over Na ₂ SO ₄ and concentrated in vacuo to provide 2-[4- (trifluoromethoxy)phenyl]-2,8-diazaspiro[5.5]undecane (2.2 g, 7.0 mmol, 54% yield) as yellow oil. It was used for next step without any purification. Step 2: Synthesis of 4-{8-[4-(trifluoromethoxy)phenyl]-2,8-diazaspiro[5.5]undecan - 2-yl}oxolan-2-one A mixture of 2-[4-(trifluoromethoxy)phenyl]-2,8-diazaspiro[5.5]undecane (1.1 g, 3.5 mmol) and 2,5-dihydrofuran-2-one (588.32 mg, 7.0 mmol) in MeOH (2.2 mL) was stirred at room temperature overnight. The mixture was concentrated in vacuo, residue dissolved in MTBE (50 mL), washed with water (2 × 50 mL), brine (30 mL) and concentrated under reduced pressure to afford 4-8-[4-(trifluoromethoxy)phenyl]- 2,8-diazaspiro[5.5]undecan-2-yloxolan-2-one (950.0 mg, 2.38 mmol, 68.1% yield, purity 78%) as a brown oil . Step 3: Synthesis of N-(4-chlorophenyl)-4-hydroxy-3-{8-[4- (trifluoromethoxy)phenyl]-2,8-diazaspiro[5.5]undecan-2-yl}bu tanamide Trimethylaluminum (287.8 mg, 3.99 mmol) was added to a solution of 4- chloroaniline (254.66 mg, 2.0 mmol) in benzene (8 mL). After stirring for 10 min, 4- 8-[4-(trifluoromethoxy)phenyl]-2,8-diazaspiro[5.5]undecan-2- yloxolan-2-one (398.0 mg, 998.95 µmol) was added to a solution and the resulting mixture was heated to 50 ^o C for 2.5 hours. After cooling to room temperature, water (3 mL) and EtOAc (15 mL) was added, filtered and the solvent was evaporated in vacuo , the residue was purified by reverse preparative HPLC to afford N-(4-chlorophenyl)-4- hydroxy-3-8-[4-(trifluoromethoxy)phenyl]-2,8-diazaspiro[5.5] undecan-2- ylbutanamide (172.9 mg, 328.71 µmol, 17% yield). LC-MS (ESI-pos): [M+H] ⁺ = 526.1 / 528.2.